CN103083354A - Compound sodium chloride eye drops - Google Patents
Compound sodium chloride eye drops Download PDFInfo
- Publication number
- CN103083354A CN103083354A CN2011103393920A CN201110339392A CN103083354A CN 103083354 A CN103083354 A CN 103083354A CN 2011103393920 A CN2011103393920 A CN 2011103393920A CN 201110339392 A CN201110339392 A CN 201110339392A CN 103083354 A CN103083354 A CN 103083354A
- Authority
- CN
- China
- Prior art keywords
- sodium chloride
- compound sodium
- eye drop
- eye drops
- accounts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses compound sodium chloride eye drops comprising the components of: sodium chloride, potassium chloride, sodium bicarbonate, hydroxypropylmethyl cellulose, an antiseptic of ethylparaben, and a solvent of water. According to the compound sodium chloride eye drops provided by the invention, a proper amount of hydroxypropylmethyl cellulose is used for regulating the viscosity, and ethylparaben is adopted as the antiseptic, such that the viscosity is appropriate, and a preservative effect is stable. The eye drops have properties similar to those of human body's own tear secretion. With the eye drops, moisture can be supplemented for eyes, eye surface can be moisturized, and a mucinous water-absorbent solution is formed and covered on the surface of eyes, such that eyes can be protected, and patient symptoms can be ameliorated. The eye drops can be used for effectively relieving and treating xerophthalmia.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, relate to a kind of artificial tears, be specifically related to a kind of compound sodium chloride eye drop solution.
Background technology
Tear is a kind of inherent protection mechanism that just has of people, and it contains lysozyme makes eyeball surface can reduce to a certain extent the infringement of infection or other harmful substances.In addition, it can also make anterior corneal surface keep smooth and produce vision clearly, and forms very thin tear film and moistening and lubricated eyeball constantly on corneal epithelium, and eyes are felt comfortably cool.
Keratoconjunctivitis sicca (also claiming xerophthalmia) is one of common disease of present ophthalmology outpatient service.Main manifestations is that eye has foreign body sensation, burning sensation and general ophthalmic uncomfortable.These discomforts typically are described as, and scrape therapy sense, eye are done, pain, grains of sand sense, sensation of pricking or burning sensation.
In recent years patients with dry eye being replenished the artificial tears is main treatment measure, namely form the normal tear film of new structure with imitated artificial tears at eyeball surface, thereby remove above-mentioned various malaise symptoms, its mechanism is to utilize various polymers to make eye drop, the long more corneal epithelium surface of sticking to can play to eyes keeping the skin wet, moistening eye surface, produce mucus water absorption solution and be covered in a surface, can make eye more comfortable.
But the artificial tears well known in the prior art time of staying on cornea is relatively short.therefore according to circumstances must be on eyes regular intervals of time use this artificial tears's therapeutic agent, this is too loaded down with trivial details and feel bad concerning the patient, although utilize known gelatinous therapeutic agent at least part of avoided this shortcoming, yet be difficult to offer the oxygen of cornea abundance when utilizing existing gelatinous therapeutic agent, in addition, the osmotic pressure of existing artificial tears and human body tear, pH value, viscosity and electrolyte concentration etc. have not being inconsistent in various degree, life-time service will cause the lipid layer of eye table to run off or be destroyed, may further increase the weight of " lipid layer ectype patients with dry eye ".
Summary of the invention
For overcoming deficiency of the prior art, the present invention aims to provide a kind of safe, effective, comfortable compound sodium chloride eye drop solution.
For realizing above-mentioned technical purpose, reach above-mentioned technique effect, the present invention is achieved through the following technical solutions.
A kind of compound sodium chloride eye drop solution comprises following component: sodium chloride, potassium chloride, sodium bicarbonate, hydroxypropyl methylcellulose also comprise the ethyl hydroxybenzoate as antiseptic.
By weight percentage, described sodium chloride accounts for 0.9%, and potassium chloride accounts for 0.014%, sodium bicarbonate accounts for 0.02%, and hydroxypropyl methylcellulose accounts for 0.3%, and ethyl hydroxybenzoate accounts for 0.03%, as solvent, the pH value of described compound sodium chloride eye drop solution is between 6.5～8.5 with water for all the other components.
Compared with prior art, the present invention has following beneficial effect:
1. compound NaCl eyedrop of the present invention has the character similar with the tear of human body self secretion; can play eyes and keep the skin wet, moistening eye surface, produce mucus water absorption solution and be covered in the eye surface; thereby play protection eyes and the effect that improves patient symptom, can effectively alleviate and treat xerophthalmia.
2. the present invention selects appropriate hydroxypropyl methylcellulose adjusting viscosity, and ethyl hydroxybenzoate is as antiseptic, and viscosity is suitable, and antiseptic effect is stable.
3. to have preparation embedding process simple and easy for compound sodium chloride eye drop solution of the present invention, and sterilizing methods is easy to operate, and product stability is high.
Above-mentioned explanation is only the general introduction of technical solution of the present invention, for can clearer understanding technological means of the present invention, and can be implemented according to the content of description, below with preferred embodiment of the present invention describe in detail bright as after.The specific embodiment of the present invention is provided by following examples.
The specific embodiment
Embodiment 1
The formula of a certain proportionate relationship of compound sodium chloride eye drop solution of the present invention and/configuration technique:
dose volume is the compound sodium chloride eye drop solution of 340L, each constituent mass is 3.06Kg sodium chloride+0.0476kg potassium chloride+0.068kg sodium bicarbonate+1.02kg hydroxypropyl methylcellulose+0.102kg ethyl hydroxybenzoate, take the sodium chloride of recipe quantity, potassium chloride, ethyl hydroxybenzoate dissolves in appropriate hot water for injection, after dissolve complete, add hydroxypropyl methylcellulose, stir under heated condition and make its complete hydration, dissolve rear filtration fully until it and add water for injection to capacity, sodium bicarbonate solution is regulated pH value between 6.5～8.5, packing, low temperature intermittently gets product after sterilization repeatedly.By " its conformance with standard as a result of Chinese pharmacopoeia standard detection.
Embodiment 2
The formula that does not add antiseptic of compound sodium chloride eye drop solution of the present invention and/configuration technique:
Dose volume is the compound sodium chloride eye drop solution of 75L, each constituent mass is 765g sodium chloride+11.9g potassium chloride+17g sodium bicarbonate+255g hydroxypropyl methylcellulose, the sodium chloride, the potassium chloride that take recipe quantity dissolve in appropriate hot water for injection, after dissolve complete, add hydroxypropyl methylcellulose, stir under heated condition and make its complete hydration, dissolve rear filtration fully until it and add water for injection to capacity, sodium bicarbonate solution is regulated pH value between 6.5～8.5, pack after packing, low temperature are intermittently sterilized repeatedly and get product.By " its conformance with standard as a result of Chinese pharmacopoeia standard detection.
During use; only need directly this eye drop to be dropped in eyeball surface; because osmotic pressure, pH value, viscosity and the electrolyte concentration etc. of this eye drop and human body tear are close; gentle as human body natural's tear for the moist feeling of eyeball; can play eyes and keep the skin wet, moistening eye surface, produce mucus water absorption solution and be covered in the eye surface; thereby play the protection eyes and improve the effect of patient symptom, to the also effect of effective alleviation and treatment of patients with dry eye.Keep sealing state before and after the use of this eye drop, to delay its oxidation deterioration effect speed.
The above is only the preferred embodiments of the present invention, is not limited to the present invention, and for a person skilled in the art, the present invention can have various modifications and variations.Within the spirit and principles in the present invention all, any modification of doing, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (7)
1. a compound sodium chloride eye drop solution, is characterized in that, comprises following component: sodium chloride, potassium chloride, sodium bicarbonate, hydroxypropyl methylcellulose.
2. compound sodium chloride eye drop solution according to claim 1, is characterized in that, also comprises antiseptic.
3. compound sodium chloride eye drop solution according to claim 2, is characterized in that, described antiseptic is ethyl hydroxybenzoate.
4. compound sodium chloride eye drop solution according to claim 1, is characterized in that, by weight percentage, described sodium chloride accounts for 0.9%, and potassium chloride accounts for 0.014%, and sodium bicarbonate accounts for 0.02%, and hydroxypropyl methylcellulose accounts for 0.3%.
5. compound sodium chloride eye drop solution according to claim 2, is characterized in that, by weight percentage, described sodium chloride accounts for 0.9%, and potassium chloride accounts for 0.014%, and sodium bicarbonate accounts for 0.02%, and hydroxypropyl methylcellulose accounts for 0.3%, and antiseptic accounts for 0.03%.
6. compound sodium chloride eye drop solution according to claim 5, is characterized in that, all the other components of described compound sodium chloride eye drop solution are water.
7. according to claim 1 or 6 described compound sodium chloride eye drop solutions, is characterized in that, the pH value of described compound sodium chloride eye drop solution is between 6.5～8.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103393920A CN103083354A (en) | 2011-11-01 | 2011-11-01 | Compound sodium chloride eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103393920A CN103083354A (en) | 2011-11-01 | 2011-11-01 | Compound sodium chloride eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103083354A true CN103083354A (en) | 2013-05-08 |
Family
ID=48196834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103393920A Pending CN103083354A (en) | 2011-11-01 | 2011-11-01 | Compound sodium chloride eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103083354A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316036A (en) * | 2013-07-17 | 2013-09-25 | 银川高新区广煜科技有限公司 | Pure natural artificial tear and its preparation method |
| CN109260221A (en) * | 2013-07-17 | 2019-01-25 | 银川高新区广煜科技有限公司 | The eyedrops and its preparation and application of pure natural components |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188368A (en) * | 2011-04-15 | 2011-09-21 | 苏州太湖美药业有限公司 | Preparation technology of compound sodium chloride eye drop solution |
-
2011
- 2011-11-01 CN CN2011103393920A patent/CN103083354A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188368A (en) * | 2011-04-15 | 2011-09-21 | 苏州太湖美药业有限公司 | Preparation technology of compound sodium chloride eye drop solution |
Non-Patent Citations (1)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典 2005年版 二部》", 31 January 2005, article "复方氯化钠滴眼液", pages: 436 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316036A (en) * | 2013-07-17 | 2013-09-25 | 银川高新区广煜科技有限公司 | Pure natural artificial tear and its preparation method |
| CN109260221A (en) * | 2013-07-17 | 2019-01-25 | 银川高新区广煜科技有限公司 | The eyedrops and its preparation and application of pure natural components |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5841151B2 (en) | Nasal spray | |
| JPH04500798A (en) | Uses of sulfated sugars | |
| CN108135926A (en) | High resiliency hyaluronic acid compositions and its application method | |
| US20080057023A1 (en) | Oxygenated ophthalmic composition | |
| CN103961556A (en) | Dendrobium officinale oculentum for relieving asthenopia | |
| CN102362924B (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
| CN102066402B (en) | Peptide derivative and composition for promoting tear secretion comprising the same | |
| WO2013044736A1 (en) | Traditional chinese medicine composition for external use in treating xerophthalmia and the preparation method thereof | |
| CN114376964B (en) | Puerarin nanoparticle film-forming hydrogel preparation and preparation method thereof | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN103007014B (en) | Traditional Chinese medicine composition used for treating xerophthalmia and preparation method thereof | |
| CN103083354A (en) | Compound sodium chloride eye drops | |
| Billowria et al. | Topical advances in mucoadhesive ocular drug delivery system | |
| ES2314284T3 (en) | THREE-LAYED LAGRIMAL FORMULATION | |
| CN106491987A (en) | A kind of treat traditional Chinese medicine fumigating steaming liquid of cataract and preparation method thereof | |
| CN109010375A (en) | A kind of collyrium | |
| CN106963770A (en) | It is a kind of to be used to prevent and treat eye drops of drying property angle/conjunctivitis and its production and use | |
| CN109982692A (en) | For treating the preparation and correlation technique of eye surface diseases | |
| CN104906029A (en) | Nasal cavity preparation and preparing method and application thereof | |
| CN107137599A (en) | A kind of anthocyanidin formula eye sticker and preparation method thereof | |
| CN112546083A (en) | Compound preparation containing sodium aescinate for relieving swelling and pain and preparation method thereof | |
| CN108366991A (en) | For treating and/or the 2-pyrrolidone-5-carboxylic acid of drying and the stimulation of pre- antiadhesion barrier and/or its salt and hyaluronic acid and/or its salt cooperate with blend and relevant pharmaceutical preparation | |
| CN110327404B (en) | Xerophthalmia moisturizing spray and preparation method thereof | |
| JP6114182B2 (en) | Ketorolac composition for corneal wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130508 |